Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), a company with a market capitalization of $3.36 million and currently holding more cash than debt on its balance sheet according to InvestingPro, announced Friday that it completed an additional closing of its private placement offering, selling 497 shares of Series D convertible preferred stock for gross proceeds of approximately $397,600. The transaction was conducted with certain institutional investors under a Securities Purchase Agreement originally dated April 21, 2025, as amended on June 25, 2025.
The Series D preferred stock is convertible into shares of the company’s common stock. According to the company, the rights and preferences of the Series D preferred stock are detailed in a certificate of designations filed with the Secretary of State of Delaware on April 22, 2025.
The offering was made without registration under the Securities Act of 1933, relying on exemptions for private placements to accredited investors. The company noted that the underlying shares of common stock will also be issued without registration upon conversion of the preferred shares.
This additional closing follows previous sales under the same agreement, including 938 shares sold on June 5, 2025, for gross proceeds of approximately $750,400, and 2,315 shares sold on June 25, 2025, for gross proceeds of approximately $1,852,000. The financing comes as the company faces challenging market conditions, with its stock down 98% over the past year and trading at $8.73.
Cero Therapeutics’ common stock and warrants trade on the Nasdaq Capital Market under the symbols CERO and CEROW, respectively.
This information is based on a statement provided in the company’s filing with the Securities and Exchange Commission.
In other recent news, Cero Therapeutics Holdings, Inc. announced a significant development as it entered a $17.5 million equity purchase agreement with an institutional investor. This agreement allows Cero Therapeutics to issue and sell additional shares of its common stock, continuing its equity line program. In another recent update, the company regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a prior notice of non-compliance due to a dip in the stock’s closing bid price. Additionally, Cero Therapeutics amended its securities purchase agreement to include new institutional investors in its Series D preferred stock sale, raising approximately $1.85 million in gross proceeds. In a positive move for the company, D. Boral (OTC:BOALY) Capital upgraded Cero Therapeutics’ stock rating from Hold to Buy, citing confidence in the company’s strategic direction and innovative approach to T cell engineering for solid tumors. Furthermore, Cero Therapeutics received Orphan Drug Designation from the FDA for its lead drug candidate CER-1236, aimed at treating acute myeloid leukemia. This designation provides several benefits, including potential marketing exclusivity and access to the FDA Orphan Drug Grants Program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.